New Study Suggests Aspirin Lowers Risk for Breast Cancer

Published Online: Tuesday, June 1, 2004

Women who took aspirin ??7 times a week showed a 26% risk reduction for developing the type of breast tumor that is stimulated by the hormone estrogen, the most common form of breast cancer. In this study, researchers compared 1442 women with all forms of breast cancer with 1420 women without the disease and conducted interviews regarding their use of aspirin.

This study adds to the body of evidence showing an association between aspirin or other nonsteroidal anti-inflammatory drug (NSAID) use and a reduced incidence of breast cancer. Researchers believe that the agents' chemopreventive effect may work via inhibition of estrogen biosynthesis.

Although the evidence is not yet sufficient to result in broad-based recommendations to use aspirin or another NSAID as protection against breast cancer, women who are at high risk for this type of breast cancer should speak with their physicians and weigh the potential benefits against the risks associated with long-term aspirin use, such as peptic ulcer and gastrointestinal bleeding.

Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291:2433-2440.

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues